Las Vegas, Nevada – (Newsfile Corp. – December 16, 2022) – TRINITY RESOURCES INC. (OTC Pink: TRRI) (the “Company” or “Trinity”) announces that, following its press release dated August 29, 2022, it has requested a name and symbol change to reflect its new name, ALZEX NEUROPHARMA INC. and its corporate action awaits final FINRA approval.

In August, the Company completed the end of the terms of the Binding Asset Purchase Agreement (the “Agreement”) whereby it acquired all of the assets and intellectual property (the “Assets”) of Alzex Biomedical Group Inc. pursuant to the terms of the Agreement Trinity issued ten million (10,000,000) Restricted Shares of Trinity Series A Convertible Shares to Alzex Biomedical Group Inc. Trinity will also advance the sum of one hundred and fifty thousand dollars (US$150,000), to be disbursed by mutual agreement within the Alzex team to settle certain outstanding debts of Alzex and to secure and reapply for additional patent protection for the acquired intellectual property. Holders of Trinity’s Series A convertible preferred stock will retain security over the intellectual property until Trinity has successfully raised the first five million dollars (US$5,000,000) to be used for pre-clinical and clinical development of the acquired Alzex assets at this point, the preferred shares are automatically converted one-for-one into ordinary shares. If Alzex stockholders have not already done so, they should contact Transhare Corporation, the Company’s registered transfer agent, at (303) 662-1112 to provide their individual stockholder information in order for their shares of Series A Convertible Preferred Stock to be converted into their possessions can be kept names.

Alzex Biomedical Group Inc. is a Canada-based development-stage biopharmaceutical company developing precision therapeutics for the treatment of Alzheimer’s disease and…